Recent news highlights Lifeward's Q2 2026 revenue growth of 16% and ongoing commercial momentum, alongside reported Q2 losses and revenue shortfalls.

• Lifeward reported Q2 2026 revenue of $6.623 million, a 16% increase compared to the prior year quarter, supported by commercial momentum [N1].
• The company reported a net loss for Q2 2026 and missed revenue estimates, reflecting ongoing challenges in profitability [N2].
• Recent earnings transcripts provide detailed operational insights for Q4 2025 and Q1 2026 [N7][N8].
• Pre-market earnings reports and other industry news provide context on Lifeward's financial performance relative to peers [N3].

Lifeward's expanding product portfolio, including next-generation exoskeletons and complementary rehabilitation technologies, supports commercial momentum. Recent FDA clearances and European certifications enhance product usability and market access. The acquisition of AlterG broadens offerings and global reach. Revenue growth in Q2 2026 indicates increasing market acceptance. Strategic distribution agreements and engagement with payors may facilitate broader adoption and reimbursement pathways.

The company continues to report net losses and faces challenges in achieving profitability. Dependence on third-party suppliers and contract manufacturers introduces operational risks. Regulatory compliance is complex and costly, with potential enforcement actions posing material risks. Reimbursement policies for exoskeleton technologies remain limited and inconsistent, potentially slowing adoption. Capital raising activities may dilute shareholders and impose operational constraints. Market competition and technological obsolescence risks persist.

Lifeward's moat is based on its proprietary robotic exoskeleton technology, including patented tilt-sensor systems and FDA clearances that enable unique ambulatory functions such as stair and curb navigation. Its acquisition of AlterG adds a complementary product line with established global distribution. Regulatory approvals and compliance with stringent quality standards create barriers to entry. Established relationships with clinics, rehabilitation centers, and distributors in key markets support market penetration. However, the company faces competition and challenges in reimbursement coverage, which may affect adoption rates.

• Regulatory Compliance Risks: Failure to comply with FDA, European MDR, and other regulatory requirements could result in enforcement actions including fines, product recalls, suspension of production, or criminal prosecution, adversely affecting operations and reputation [S1].
• Reimbursement and Market Adoption Risks: Limited and inconsistent reimbursement policies for exoskeleton technologies in the U.S. and other markets may slow customer adoption and impact revenue growth [S1].
• Operational and Supply Chain Risks: Dependence on third-party suppliers and contract manufacturers for components and products introduces risks related to supply disruptions, quality control, and cost increases [S1].
• Financial and Liquidity Risks: The company has reported net losses and relies on capital raises and debt financing to fund operations. Limitations on equity offerings and potential dilution pose risks to financial stability [S2].
• Legal and Compliance Risks: Lifeward is subject to anti-bribery laws, data privacy regulations such as HIPAA and GDPR, and cybersecurity threats, with violations potentially resulting in significant penalties and reputational harm [S1].

• Lifeward Ltd. is a medical device company focused on designing, developing, and commercializing solutions for physical rehabilitation and recovery, including robotic exoskeletons and biomedical pipeline products [S1].
• The company’s initial products include the ReWalk Personal and ReWalk Rehabilitation Exoskeleton devices for individuals with spinal cord injury (SCI), enabling ambulatory functions with patented tilt-sensor technology and motorized legs [S1].
• In March 2023, Lifeward received FDA 510(k) clearance for the ReWalk Personal Exoskeleton with stair and curb functionality, expanding its use in real-world environments in the U.S. [S1].
• In March 2025, the company received FDA 510(k) clearance for the ReWalk 7 Personal Exoskeleton, a next-generation model [S1].
• Lifeward developed the ReStore Exo-Suit device for rehabilitation of individuals with lower limb disabilities due to stroke; sales in the EU ceased in May 2024 [S1].
• The company distributes MYOLYN MyoCycle FES Pro cycles in the U.S., with distribution rights no longer exclusive [S1].
• In August 2023, Lifeward acquired AlterG, a provider of Anti-Gravity systems used in physical and neurological rehabilitation, with over 6,000 facilities globally [S1].
• Lifeward has distribution agreements to expand market penetration, including with CorLife for workers’ compensation market in the U.S. and Verita Neuro for certain international markets [S1].
• Principal markets are primarily the U.S. and Europe, with some sales in Asia, Middle East, and South America; sales are direct in the U.S. and through distributors in other regions [S1].
• Revenue is generated from sales of ReWalk, AlterG, ReStore, and MyoCycle systems, extended warranties, and repair services [S2].
• For the quarter ended June 30, 2026, revenue was $6.623 million, up from $5.724 million in the same period in 2025, representing a 16% increase [S2][N1].
• Net loss for the quarter ended June 30, 2026 was $10.793 million, compared to $4.834 million in the same period in 2025 [S2][N2].
• Basic and diluted net loss per share for the quarter ended June 30, 2026 was $4.12 [S2].
• The company’s cash and cash equivalents as of June 30, 2026 were $9.448 million, with current assets of $25.947 million and current liabilities of $11.159 million, resulting in a current ratio of 2.33 and a cash ratio of 0.85 [S2].
• Lifeward transitioned manufacturing of ReWalk products to in-house in Q2 2025 to reduce costs and improve quality control, terminating prior contract manufacturing agreements [S1].
• The company relies on third-party suppliers and contract manufacturer Cirtronics for AlterG products and components, with purchase orders based on sales forecasts [S1].
• Lifeward is subject to extensive regulatory requirements including FDA clearances, European MDR certification, and compliance with quality management systems such as ISO 13485:2016 [S1].
• Failure to comply with regulatory requirements could lead to enforcement actions including fines, recalls, suspension of production, or criminal prosecution [S1].
• The company faces risks related to reimbursement coverage, as broad uniform policies for exoskeleton technologies do not currently exist in the U.S., though it engages with CMS and other payors [S1].
• Lifeward has raised capital through equity offerings and convertible notes, including a strategic transaction with Oramed in early 2026 involving issuance of shares and convertible notes [S2][Q3][Q4].
• The company’s operating expenses increased notably in recent periods, including research and development, sales and marketing, and general and administrative expenses, partly due to strategic transactions and financing activities [S2].
• Lifeward’s liquidity position includes contractual obligations for purchase orders and operating leases, with total obligations of approximately $13.9 million as of June 30, 2026 [S2].
• The company is subject to various legal and regulatory risks including anti-bribery laws, data privacy regulations such as HIPAA and GDPR, and cybersecurity risks [S1].
• Recent news highlights include Q2 2026 revenue growth of 16% and commercial momentum supporting the second half of the year, alongside reported Q2 losses and revenue shortfalls [N1][N2].
• The company’s recent earnings transcripts and news releases provide detailed operational and financial updates through mid-2026 [N7][N8].